Clinigen acquires Link
Company issues new shares and appoints Group Chairman and Founder of Link to the board
Clinigen, a global speciality pharmaceuticals business, has completed the acquisition of Link Healthcare, which was announced on 22 September 2015.
As a result of the acquisition, 3,102,558 new ordinary shares in the group have been allotted, credited as fully paid, to the vendors of Link.
Accordingly, the group now has 114,553,730 ordinary shares in issue of 0.1p each, with voting rights. Clinigen does not hold any shares in treasury.
This figure of 114,553,730 ordinary shares may be used by Clinigen shareholders to determine whether they are required to notify their interest in, or a change in their interest in, Clinigen under the Financial Conduct Authority's Disclosure and Transparency Rules.
Peter George, Chief Executive of Clinigen, said: ’The completion of this strategic acquisition strengthens our international distribution network across the AAA region (Asia, Africa and Australasia). We welcome Link to the group and look forward to being even better placed to directly supply much needed, but not always licensed, medicines into the growing ‘pharmerging’ markets.
‘Together, our combined entity further supports our underlying philosophy of getting the right drug to the right patient at the right time regardless of the location anywhere in the world,’ he added.
Upon completion, John Bacon, Group Chairman and Founder of Link, was appointed to the Clinigen Board as a Non-Executive Director.
